Global Glioblastoma Multiforme (GBM) Treatment Market Projected to Grow at 10.5% CAGR, Reaching $4.06 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Glioblastoma Multiforme (GBM) Treatment Industry Market Size Be by 2025?
Significant expansion has been observed within the glioblastoma multiforme (gbm) treatment sector recently, projecting an increase in market valuation from $2.48 billion in 2024 to $2.73 billion come 2025, which translates to a compound annual growth rate (CAGR) of 9.8%; this upward trajectory during the past period stems from factors such as the rising occurrence and widespread nature of the disease, progress made in methods of diagnosis, boosted financial support for clinical investigations and research endeavors, the formation of strategic alliances, and a deeper comprehension of the biological mechanisms driving tumor development.

What's the Long-Term Growth Forecast for the Glioblastoma Multiforme (GBM) Treatment Market Size Through 2029?
Anticipation surrounds the glioblastoma multiforme (gbm) treatment market, forecasting substantial expansion in the ensuing years, projecting a valuation of $4.06 billion by 2029, driven by a compound annual growth rate (CAGR) of 10.5% during this timeframe. This accelerated upswing is fundamentally linked to several key factors, notably the burgeoning field of immunotherapies, significant strides in precision medicine, deeper comprehension of underlying genetic indicators, heightened advocacy efforts and general public awareness, and supportive governmental initiatives directed toward rare ailment management. Within the scope of this forecast, notable emerging currents encompass the active investigation into combined therapeutic modalities, the increasing incorporation of artificial intelligence for refining both diagnostic procedures and treatment strategy formulation, the escalating uptake of immune-based interventions, alongside the continuous development of sophisticated medical instrumentation and apparatus.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Glioblastoma Multiforme (GBM) Treatment Market Expansion?
The rising incidence of conditions affecting the brain promises to stimulate expansion within the glioblastoma multiforme (GBM) therapy sector moving ahead. These cerebral ailments encompass deviations from normal operation in both the brain itself and the network of nerves extending through the human physique and spinal column. Factors like an expanding elderly demographic, weakened immune responses, enhanced diagnostic capabilities leading to more detections, exposure to ionizing radiation, widespread air contamination, and several other elements contribute to the escalation of brain disorders such as glioblastoma multiforme (GBM), thereby necessitating therapeutic interventions to enhance overall quality of life. To illustrate the scale, the American Cancer Society, a US-based non-profit organization focused on cancer eradication, documented approximately 25,050 diagnoses of malignant tumors affecting the brain or spinal cord within the United States during 2022. Consequently, this growing frequency of neurological disorders directly fuels the upward trend in the market for glioblastoma multiforme (GBM) treatments.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

What Are the Key Trends Driving Glioblastoma Multiforme (GBM) Treatment Market Growth?
Leading enterprises within this sector are concentrating their efforts on creating cutting-edge, wearable, and easily transportable gadgets as a means of securing their ongoing prominence. These forward-thinking developments are intended to furnish end-users with superior capabilities, ease of use, and a high degree of wearability, thereby satisfying the increasing consumer desire for readily available and highly effective medical care options. A notable illustration from 2023 involves Novocare, an oncology firm situated in Jersey, which introduced Optune Gio, a portable and wear-on treatment apparatus cleared by the FDA for individuals recently diagnosed with glioblastoma (GBM). This apparatus utilizes what are termed Tumor Treating Fields (TTFields), essentially alternating electrical fields engineered to impede the proliferation of malignant cells, which offers the possibility of prolonging patient lifespans. Weighing a mere 2.7 pounds, the design of Optune Gio prioritizes patient ease, permitting continuous utilization throughout their ordinary routines.

How Is the Glioblastoma Multiforme (GBM) Treatment Market Segmented?
The glioblastoma multiforme (gbm) treatmentmarket covered in this report is segmented -

1) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Tumor Treating Field (TTF) Therapy; Immunotherapy
2) By Drug Class: Temozolomide; Bevacizumab; Lomustine; Carmustine Wafers; Other Drug Classes
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
4) By End-Use: Hospitals; Clinics; Ambulatory Surgical Centers

Subsegments:
1) By Surgery: Tumor Resection; Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy; Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors; Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors; Vaccine-Based Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8803&type=smp

Which Companies Are Leading the Charge in Glioblastoma Multiforme (GBM) Treatment Market Innovation?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

Which Regions Are Leading the Global Glioblastoma Multiforme (GBM) Treatment Market in Revenue?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.